NeuroSense Therapeutics has filed a patent application in the U.S. for using PrimeC, a combination of ciprofloxacin and celecoxib, to treat traumatic brain injury (TBI) and its long-term effects like chronic traumatic encephalopathy (CTE). This move aims to expand PrimeC's potential beyond ALS into a large market with no current disease-modifying therapies. The patent, if granted, could protect this use until 2047 and supports future research collaborations. NeuroSense continues to prioritize ALS but is exploring TBI as a strategic growth area.
NeuroSense Therapeutics' recent U.S. patent application for traumatic brain injury treatment provides context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:43 WIB: Among 150 priced health-sector US stocks, 68 rose and 54 fell today. Notable movers include MRNA (Moderna, Inc.) at USD 215.33 with a -1.23% change and a typical hold time of 59 days, IMVT (Immunovant Inc.) at USD 27.05 with a +1.20% change and a 10-day hold time, and ERAS (Erasca Inc.) at USD 13.55 with a +1.19% change and a 2-day hold time.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
